Viking Therapeutics, Inc.VKTX
| Dec 31,
2015 | Dec 31,
2016 | Dec 31,
2017 | Dec 31,
2018 | Dec 31,
2019 | Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 | Dec 31,
2023 | Dec 31,
2024 |
|---|
| Net loss | - | - | - | -22 | -26 | -39 | -55 | -69 | -86 | -110 |
|---|
| (Accretion) amortization of investment premiums | - | - | - | - | - | - | - | - | 8 | 17 |
|---|
| Amortization of financing costs | - | 138,701 | 571,044 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|---|
| Stock-based compensation | 3 | 2 | 1 | 3 | 4 | 6 | 6 | 9 | 17 | 30 |
|---|
| Amortization of right-of-use assets | - | - | - | - | - | - | - | 0 | 0 | 0 |
|---|
| Realized gain on investment | - | - | - | - | - | - | - | - | - | 0 |
|---|
| Operating Leases Interest Expense | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
|---|
| Prepaid expenses and other current assets | 1 | -273,329 | -497,626 | 0 | 7 | -0 | 1 | 3 | -6 | -0 |
|---|
| Accrued interest, net of interest receivable on maturity of investments | - | - | - | - | - | -3 | -1 | -1 | -0 | -1 |
|---|
| Accounts payable | 219,237 | 677,185 | 263,509 | -1 | 1 | 2 | -3 | 7 | -1 | 2 |
|---|
| Accrued expenses | 2 | -141,295 | 1 | 1 | 2 | 4 | -1 | 6 | -2 | 6 |
|---|
| Lease liability | - | - | - | - | -0 | -0 | -0 | -0 | -0 | -0 |
|---|
| Net cash used in operating activities | - | - | - | -19 | -25 | -22 | -48 | -48 | -73 | -88 |
|---|
| Purchases of investments | 16 | 17 | 23 | 348 | 362 | 281 | 168 | 121 | 478 | 1,113 |
|---|
| Proceeds from sales and maturities of investments | 3 | 20 | 21 | 82 | 370 | 322 | 206 | 176 | 299 | 560 |
|---|
| Net cash (used in) provided by investing activities | - | - | - | -266 | 7 | 42 | 38 | 55 | -179 | -553 |
|---|
| Public offering, net of offering costs | - | - | - | - | - | - | - | - | -270 | -597 |
|---|
| Value of shares withheld related to employee tax withholding | 418,412 | 31,061 | 21,712 | 0 | 0 | 0 | 1 | 2 | 7 | 42 |
|---|
| Repurchase of common stock | 38 | 229 | - | - | - | - | - | 7 | - | - |
|---|
| Proceeds From Warrant And Option Exercises And Stock Issuance Under Employee Stock Purchase Plan | - | - | - | - | - | - | - | 1 | 7 | 11 |
|---|
| ATM offering, net of fees | - | - | - | - | - | - | - | 12 | 2 | 47 |
|---|
| Net cash provided by financing activities | - | - | - | 300 | 1 | 1 | 7 | 4 | 271 | 612 |
|---|
| Net (decrease) increase in cash and cash equivalents | - | - | - | - | - | - | - | - | 19 | -29 |
|---|
| Effect of exchange rate changes on cash | - | - | - | - | - | - | - | -0 | -0 | -0 |
|---|
| Unpaid deferred public offering and other financing costs | - | - | 139,585 | - | 0 | 0 | 0 | 0 | 0 | 0 |
|---|
| Right-of-use asset obtained in exchange for lease obligation | - | - | - | - | - | - | - | 2 | - | 0 |
|---|